Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Pradaxa (dabigatran etexilate) – Oral Direct Thrombin Inhibitor

Pradaxa is a new oral anticoagulant under development by Boehringer Ingelheim. It has a rapid onset and offset of action and predictable anticoagulation action, eliminating the need for coagulation monitoring.

  • human heart
  • Venous thromboembolism
  • Risk of developing DVT or PE
  • Oral anticoagulants
  • Pradaxa (dabigatran etexilate)

Go Top